First, we analyzed CD33dimHLA-DRlow/−CD66b+Lin− PMN- and CD33+HLA-DRlow/−CD14+ M-MDSC in PBMC from melanoma patients and their non-suppressive MDSC counterparts from HD by flow cytometry. This evidence concerns the gene CD33 and melanoma.